Complete Up To Date Information about Slentrol™.
NADA Number: 141-260 | |
| Proprietary Name |
Slentrol™ |
|---|---|
| Sponsor |
Pfizer, Inc. |
| Sponsor Address |
235 East 42d St. New York, NY 10017 USA |
| Ingredients |
Dirlotapide |
| Species |
Dog, no use class stated or implied |
| Routes of Administration |
Per Os |
| Dose Form |
Liquid (solution) |
| Drug Form |
Liquid (solution) |
| Dispensing Status |
RX |
| Patent Number |
6720351 |
| Exclusivity |
Exclusivity granted because the active ingredient of this new animal drug has not previously been approved. |
| Withdrawal Time |
Withdrawal times do not apply to the species listed for this product. |
|
Dosage Amount, Indications & Limitations |
520.666 Dirlotapide Specifications: Each milliliter (mL) of solution contains 5 milligrams (mg) dirlotapide. Conditions of use: Dogs Amount: The initial dosage is 0.01 mL/kg (0.0045 mL/lb body weight for the first 14 days. After the first 14 days of treatment, the dose volume is doubled to 0.02 mL/kg (0.009 mL/lb) body weight for the next 14 days (days 15 to 28 of treatment). Dogs should be weighed monthly and the dose volume adjusted every month, as necessary, to maintain a target percent weight loss until the desired weight is achieved. Indications for use: For the management of obesity. Limitations: Federal law restricts this drug to use by or on the order of a licensed veterinarian. |